Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma Journal Article
| Authors: | Voss, M. H.; Hsieh, J. J.; Motzer, R. J. |
| Article Title: | Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma |
| Abstract: | Abstract: In recent years, functional characterization of the von Hippel-Lindau tumor suppressor, hypoxia-induced factors, and one of their key downstream effectors, the vascular endothelial growth factor (VEGF), has revolutionized treatment of advanced renal cell carcinoma. Therapeutic strategies targeting the ligand itself (VEGF-A) or its receptor (VEGFR2) have proven successful. However, complete remissions are rare, and with time patients invariably suffer disease progression. It is understood that this is due to incomplete suppression of VEGF signaling and/or adaptive up-regulation of non-VEGF-dependent tumor-promoting stimuli. In this article, we review novel VEGF-directed agents that are being developed to address the shortcomings of current targeted drugs for the treatment of advanced renal cell carcinoma. Building on our current understanding of molecular mechanisms behind resistance, examples include next-generation multitarget tyrosine kinase inhibitors, biologics, and other compounds. © 2013 Lippincott Williams & Wilkins. |
| Keywords: | vasculotropin; vascular endothelial growth factor a; fatigue; review; sorafenib; raf protein; sunitinib; diarrhea; hypertension; drug approval; drug targeting; neurotoxicity; nuclear magnetic resonance imaging; neoplasm; vasculotropin receptor; progression free survival; protein kinase inhibitor; tumor biopsy; food and drug administration; drug resistance; enzyme activity; platelet derived growth factor receptor; angiogenesis; renal cell carcinoma; kidney carcinoma; protein tyrosine kinase inhibitor; protein kinase inhibitors; cancer size; vascular endothelial growth factor; vasculotropin a; cediranib; pazopanib; maximum tolerated dose; von hippel lindau disease; axitinib; ic 50; hand foot syndrome; heart left ventricle ejection fraction; protein ret; b raf kinase; platelet derived growth factor beta receptor; hemoptysis; investigational; receptors; therapies; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); vascular endothelial growth factors; multicenter study (topic); fibroblast growth factor receptor; biological agents; cabozantinib; tivozanib; regorafenib; dovitinib; von hippelylindau disease; foretinib; lenvatinib; ramucirumab |
| Journal Title: | The Cancer Journal |
| Volume: | 19 |
| Issue: | 4 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2013-07-01 |
| Start Page: | 299 |
| End Page: | 306 |
| Language: | English |
| DOI: | 10.1097/PPO.0b013e31829d5cff |
| PROVIDER: | scopus |
| PUBMED: | 23867510 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 4 September 2013" - "CODEN: CAJOC" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work